[2023. 11. 28.][NASDAQ:MGRM]Monogram Orthopaedics Delivers First Surgical Robot

[2023. 11. 28.][NASDAQ:MGRM]Monogram Orthopaedics Delivers First Surgical Robot

Monogram Orthopaedics Achieves Major Milestone with First Surgical Robot Delivery

AUSTIN, TX / ACCESSWIRE / November 28, 2023 / Monogram Orthopaedics Inc. (NASDAQ:MGRM), a trailblazing medical technology company specializing in reconstructive joint procedures and surgical robotics, has reached a significant turning point in its journey. The company recently completed the delivery of its inaugural surgical robot to one of the world's leading global robotics distributors.

This milestone marks a monumental achievement for Monogram Orthopaedics and serves as a pivotal moment in their strategic roadmap. CEO Ben Sexson expressed his excitement, stating, "Delivering our first robot and realizing our first commercial revenues validates our technology and represents a pivotal milestone for our strategic roadmap. Our system is performing at an extremely high level. We now look forward to seeing how our robot competes and scales in the real world. We hope to see the mBôs robot contribute to advancing the standard of care for orthopedic patients worldwide."

Monogram's mission is to elevate the standard of care in orthopedic joint replacement surgery through cutting-edge, next-generation active surgical robotics. Remarkably, despite advances in technology, approximately 88% of knee replacement surgeries (the Company's initial target market) are still conducted manually. The mBôs robot aims to revolutionize the field by combining safety, user-friendliness, cost-efficiency, innovative implant design, extensive clinical capabilities, and speed to drive the next wave of robotic adoption in orthopedics.

About Monogram Orthopaedics

Monogram Orthopaedics (NASDAQ: MGRM) is at the forefront of developing a product solution architecture with the ultimate goal of enabling patient-optimized orthopedic implants on a large scale by integrating 3D printing and robotics with advanced pre-operative imaging. The Company has a robot prototype capable of autonomously executing optimized paths for the precise insertion of implants in synthetic bone specimens. Monogram intends to manufacture and market robotic surgical equipment, related software, orthopedic implants, tissue ablation tools, navigation consumables, and other essential instrumentation required for reconstructive joint replacement procedures. It's important to note that the Company has not yet submitted 510(k) premarket notifications or obtained 510(k) clearances for its robotic products, as FDA approval is required for marketing such products.

Monogram Orthopaedics is on a mission to transform the landscape of orthopedic surgery. Their system aims to combine personalized knee implants with precision robotic surgical assistants to provide patients with better-fitting knee replacements through minimally invasive surgery. With a market of $19.4 billion and approximately 100,000 knee replacements failing each year, this presents a tremendous opportunity for the company.

For more information, please visit www.monogramorthopedics.com.

Forward-Looking Statements

This press release may contain "forward-looking statements." These statements pertain to Monogram Orthopaedics Inc.'s financial projections, business plans, product expectations, or other forecasts about future events. Such statements are identified by words such as "should," "may," "intends," "anticipates," "believes," "estimates," "projects," "forecasts," "expects," "plans," and "proposes."

While Monogram Orthopaedics Inc. believes that these forward-looking statements are based on reasonable assumptions, there are inherent risks and uncertainties that could cause actual results to differ materially. It is advisable to carefully review and consider any cautionary statements and other disclosures, including those under the "Risk Factors" section and elsewhere in the SEC filing. Forward-looking statements are only valid as of the document's date, and Monogram Orthopaedics Inc. does not commit to updating them except as required by law.

Investor Relations

Chris Tyson Executive Vice President MZ North America Direct: 949-491-8235 MGRM@mzgroup.us

SOURCE: MONOGRAM ORTHOPAEDICS INC